tradmap

LBRX Earnings LB PHARMACEUTICALS INC

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$176 -$88 $0 2024 2025
EPS
Net income (annual)
-$63M -$32M $0 2024 2025
Net income
Return on equity (annual)
-8% 29% 67% 0% 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$162 -$81 $0 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$52M -$26M $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-16% 10% 36% 0% Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–8 of 8
Q2 20262026-06-30-2.422026-08-1110-Q
Q1 20262026-03-31-0.672026-05-1210-Q
FY 20252025-12-31-3.132026-03-2610-K
Q3 20252025-09-30-6.262025-11-0610-Q
Q2 20262025-06-30-28.362026-08-1110-Q
Q1 20262025-03-31-14.792026-05-1210-Q
FY 20252024-12-31-176.152026-03-2610-K
Q3 20252024-09-30-162.152025-11-0610-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.